Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy

References

• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–853. doi:10.1053/j.gastro.2015.12.04126795574
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255. doi:10.1016/S0140-6736(11)61347-022353262
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022. doi:10.1002/hep.2419921374666
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943. doi:10.1016/j.jhep.2011.12.00122424438
   PubMed Web of Science ®Google Scholar
• Mokdad AA, Hester CA, Singal AG, et al. Management of hepatocellular in the United States. Chin Clin Oncol. 2017;6:21. doi:10.21037/cco28482674
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res. 2019;144:19–50. doi:10.1016/j.phrs.2019.03.00630877063
   PubMed Web of Science ®Google Scholar
• Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. J Semin Oncol. 2012;39:486–492. doi:10.1053/j.seminoncol.2012.05.005
   PubMed Web of Science ®Google Scholar
• Zhu YJ, Zheng B, Wang HY, et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38:614–622. doi:10.1038/aps.2017.528344323
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.18650514
   PubMed Web of Science ®Google Scholar
• Jackson R, Psarelli EE, Berhane S, et al. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized Phase III trials. J Clin Oncol. 2017;35:622–628. doi:10.1200/JCO.2016.69.519728045619
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. doi:10.1016/S1470-2045(08)70285-719095497
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821–829. doi:10.1016/j.jhep.2012.06.01422727733
   PubMed Web of Science ®Google Scholar
• Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172–179. doi:10.1200/JCO.2013.54.329825488963
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–4075. doi:10.1200/JCO.2012.45.837224081937
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517–3524. doi:10.1200/JCO.2012.48.441023980084
   PubMed Web of Science ®Google Scholar
• Pan T, Li XS, Xie QK, et al. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. Clin Radiol. 2014;69:e553–e561. doi:10.1016/j.crad.2014.09.00725304928
   PubMed Web of Science ®Google Scholar
• Liu PH, Lee YH, Hsia CY, et al. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol. 2014;21:1825–1833. doi:10.1245/s10434-014-3510-324499831
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang C, Zhao Y, et al. Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients. Biomed Res Int. 2014;2014:194278.24800212
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64:1090–1098. doi:10.1016/j.jhep.2016.01.01226809111
   PubMed Web of Science ®Google Scholar
• Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117–2127. doi:10.1016/j.ejca.2011.05.00721664811
   PubMed Web of Science ®Google Scholar
• Ohki T, Sato K, Yamagami M, et al. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clin Drug Investig. 2015;35:751–759. doi:10.1007/s40261-015-0333-3
   PubMed Web of Science ®Google Scholar
• Hu H, Duan Z, Long X, et al. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS ONE. 2014;9:e96620. doi:10.1371/journal.pone.009662024817002
   PubMed Web of Science ®Google Scholar
• Li L, Zhao W, Wang M, et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2018;18:138. doi:10.1186/s12876-018-0849-030180810
   PubMed Web of Science ®Google Scholar
• Nour-Eldin NA, Exner S, Al-Subhi M, et al. Ablation therapy of non-colorectal cancer lung metastases: retrospective analysis of tumour response post-laser-induced interstitial thermotherapy (LITT), radiofrequency ablation (RFA) and microwave ablation (MWA). Int J Hyperthermia. 2017;33:820–829. doi:10.1080/02656736.2017.130665628540791
   PubMed Web of Science ®Google Scholar
• Prins FM, Kerkmeijer LGW, Pronk AA, et al. Renal cell carcinoma: alternative nephron-sparing treatment options for small renal masses, a systematic review. J Endourol. 2017;31:963–975. doi:10.1089/end.2017.038228741377
   PubMed Web of Science ®Google Scholar
• Korkusuz Y, Gröner D, Raczynski N, et al. Thermal ablation of thyroid nodules: are radiofrequency ablation, microwave ablation and high intensity focused ultrasound equally safe and effective methods? Eur Radiol. 2018;28:929–935. doi:10.1007/s00330-017-5039-x28894936
   PubMed Web of Science ®Google Scholar
• Andreano A, Huang Y, Meloni MF, et al. Microwaves create larger ablations than radiofrequency when controlled for power in ex vivo tissue. Med Phys. 2010;37:2967–2973. doi:10.1118/1.343256920632609
   PubMed Web of Science ®Google Scholar
• Brace CL, Hinshaw JL, Laeseke PF, et al. Pulmonary thermal ablation: comparison of radiofrequency and microwave devices by using gross pathologic and CT findings in a swine model. Radiology. 2009;251:705–711. doi:10.1148/radiol.251308156419336667
   PubMed Web of Science ®Google Scholar
• Gillams AR, Lees WR. Radiofrequency ablation of lung metastases: factors influencing success. Eur Radiol. 2008;18:672–677. doi:10.1007/s00330-007-0811-y18008074
   PubMed Web of Science ®Google Scholar
• Crocetti L, Bozzi E, Faviana P, et al. Thermal ablation of lung tissue: in vivo experimental comparison of microwave and radiofrequency. Cardiovasc Intervent Radiol. 2010;33:818–827. doi:10.1007/s00270-010-9869-z20442998
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711. doi:10.1093/jnci/djn13418477802
   PubMed Web of Science ®Google Scholar
• Wáng YX, De Baere T, Idée JM, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res. 2015;27:96–121. doi:10.3978/j.issn.1000-9604.2015.03.0325937772
   PubMed Web of Science ®Google Scholar
• Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol. 2012;39:503–509. doi:10.1053/j.seminoncol.2012.05.00422846867
   PubMed Web of Science ®Google Scholar
• Farinati F, Giacomin A, Vanin V, et al. TACE treatment in hepatocellular carcinoma: what should we do now? J Hepatol. 2012;57:221–222. doi:10.1016/j.jhep.2011.12.02222286000
   PubMed Web of Science ®Google Scholar
• Xu LF, Sun HL, Chen YT, et al. Large primary hepatocellular carcinoma: transarterialchemoembolization monotherapy versus combined transarterialchemoembolization-percutaneous microwave coagulationtherapy. J Gastroenterol Hepatol. 2013;28:456–463. doi:10.1111/jgh.1208823216261
   PubMed Web of Science ®Google Scholar
• Chen QF, Jia ZY, Yang ZQ, et al. Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-microwave ablation therapy for hepatocellular carcinoma tumors ≤5 cm: a propensity analysis at a single center. Cardiovasc Intervent Radiol. 2017;40:1748–1755. doi:10.1007/s00270-017-1736-828681222
   PubMed Web of Science ®Google Scholar
• Veltri A, Gazzera C, Calandri M, et al. Percutaneous treatment of Hepatocellular carcinoma exceeding 3 cm: combined therapy or microwave ablation? Preliminary results. Radiol Med. 2015;120:1177–1183. doi:10.1007/s11547-015-0550-026025419
   PubMed Web of Science ®Google Scholar
• Filippiadis DK, Binkert C, Pellerin O, et al. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40:1141–1146. doi:10.1007/s00270-017-1703-428584945
   PubMed Web of Science ®Google Scholar
• Zhu K, Huang J, Lai L, et al. Medium or large hepatocellular carcinoma: sorafenib combined with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;288:300–307. doi:10.1148/radiol.201817202829688153
   PubMed Web of Science ®Google Scholar
• Peng Z, Chen S, Wei M, et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;287:705–714. doi:10.1148/radiol.201817154129390197
   PubMed Web of Science ®Google Scholar
• Huang M, Wang L, Chen J, et al. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery. Int J Oncol. 2016;48:2144–2154. doi:10.3892/ijo.2016.342126984380
   PubMed Web of Science ®Google Scholar
• Ni JY, Xu LF, Wang WD, et al. Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model. J Cancer Res Clin Oncol. 2017;143:199–207. doi:10.1007/s00432-016-2237-x27638772
   PubMed Web of Science ®Google Scholar
• Chao Y, Chung YH, Han G, et al. Study in Asia of the combination of transarterial chemoembolization (TACE) with sorafenib in hepatocellular carcinoma trial (START): second interim safety and efficacy analysis. J Clin Oncol. 2010;28:4026. doi:10.1200/jco.2010.28.15_suppl.4026
   Web of Science ®Google Scholar
• Hu H, Chen GF, Yuan W, et al. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis. Int J Hyperthermia. 2018;34:1351–1358. doi:10.1080/02656736.2018.146253629720001
   PubMed Web of Science ®Google Scholar
• Smolock AR, Cristescu MM, Hinshaw A, et al. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom Radiol (NY). 2018;43:2497–2504. doi:10.1007/s00261-018-1464-929450606
   PubMed Web of Science ®Google Scholar
• Ni JY, Liu SS, Xu LF, et al. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2013;139:653–659. doi:10.1007/s00432-012-1369-x23292073
   PubMed Web of Science ®Google Scholar
• Sun JJ, Zhao HJ, Li W. Clinical study of radiofrequency ablation therapy in combination with sorafenib for advanced hepatocellular carcinoma. J Clin Hepatol. 2011;27:1093–1098.
   Google Scholar
• Xie H, Tian S, Yu H, et al. A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma. Onco Targets Ther. 2018;11:3257–3265. doi:10.2147/OTT29910621
   PubMed Web of Science ®Google Scholar